Russell Schundler Sells 2,060 Shares of Liquidia Co. (NASDAQ:LQDA) Stock

Liquidia Co. (NASDAQ:LQDA) General Counsel Russell Schundler sold 2,060 shares of the firm’s stock in a transaction that occurred on Friday, April 12th. The stock was sold at an average price of $14.58, for a total transaction of $30,034.80. Following the sale, the general counsel now directly owns 486,027 shares of the company’s stock, valued at approximately $7,086,273.66. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

Russell Schundler also recently made the following trade(s):

• On Monday, March 18th, Russell Schundler sold 8,653 shares of Liquidia stock. The stock was sold at an average price of $15.82, for a total transaction of $136,890.46.

Liquidia Stock Up 2.1 %

Shares of LQDA stock opened at $13.86 on Thursday. Liquidia Co. has a 52-week low of $5.71 and a 52-week high of $16.99. The firm’s 50 day moving average price is $14.75 and its two-hundred day moving average price is $10.95.

Liquidia (NASDAQ:LQDA) last announced its quarterly earnings data on Wednesday, March 13th. The company reported ($0.42) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.23) by ($0.19). Liquidia had a negative net margin of 448.89% and a negative return on equity of 132.16%. The business had revenue of $4.53 million during the quarter, compared to the consensus estimate of $5.29 million. As a group, sell-side analysts expect that Liquidia Co. will post -1.01 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several research firms have recently commented on LQDA. HC Wainwright increased their price target on shares of Liquidia from $16.00 to $32.00 and gave the company a “buy” rating in a research note on Thursday, March 14th. Bank of America increased their price target on shares of Liquidia from $13.00 to $15.00 and gave the company a “buy” rating in a research note on Thursday, December 21st. Needham & Company LLC reissued a “buy” rating and set a $28.00 price target on shares of Liquidia in a research note on Wednesday, April 10th. Wedbush reissued an “underperform” rating and set a $3.00 price target on shares of Liquidia in a research note on Thursday, December 21st. Finally, LADENBURG THALM/SH SH increased their price target on shares of Liquidia from $15.00 to $30.00 and gave the company a “buy” rating in a research note on Thursday, December 21st. One analyst has rated the stock with a sell rating and four have assigned a buy rating to the stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $21.00.

Hedge Funds Weigh In On Liquidia

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Fortitude Family Office LLC bought a new position in shares of Liquidia during the fourth quarter worth $26,000. Tower Research Capital LLC TRC boosted its position in shares of Liquidia by 101.3% during the second quarter. Tower Research Capital LLC TRC now owns 7,004 shares of the company’s stock worth $55,000 after purchasing an additional 3,524 shares in the last quarter. UBS Group AG boosted its position in shares of Liquidia by 134.0% during the second quarter. UBS Group AG now owns 7,948 shares of the company’s stock worth $35,000 after purchasing an additional 4,552 shares in the last quarter. Legal & General Group Plc bought a new position in shares of Liquidia during the second quarter worth $38,000. Finally, Tower Research Capital LLC TRC boosted its position in shares of Liquidia by 610.7% during the fourth quarter. Tower Research Capital LLC TRC now owns 8,997 shares of the company’s stock worth $108,000 after purchasing an additional 7,731 shares in the last quarter. 64.54% of the stock is owned by institutional investors.

About Liquidia

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).